Suresh Mahabhashyam
Chief Tech/Sci/R&D Officer chez CORVUS PHARMACEUTICALS, INC.
Profil
Suresh Mahabhashyam is currently working as the Vice President-Clinical Development at Corvus Pharmaceuticals, Inc. He previously worked as the Senior Medical Director at Alexion Pharmaceuticals, Inc. from 2012 to 2015 and as the Vice President-Safety & Risk Management at Infinity Pharmaceuticals, Inc. from 2018 to 2019.
Dr. Mahabhashyam holds a graduate degree from the University of North Texas Health Science Center and a doctorate degree from Bangalore Medical College & Research Institute.
Postes actifs de Suresh Mahabhashyam
| Sociétés | Poste | Début |
|---|---|---|
| CORVUS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2020 |
Anciens postes connus de Suresh Mahabhashyam
| Sociétés | Poste | Fin |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2019 |
| ALEXION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2015 |
Formation de Suresh Mahabhashyam
| University of North Texas Health Science Center | Graduate Degree |
| Bangalore Medical College & Research Institute | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CORVUS PHARMACEUTICALS, INC. | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
